Piper Sandler Maintains Overweight on ASLAN Pharma, Lowers Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Edward Tenthoff has maintained an Overweight rating on ASLAN Pharma (NASDAQ:ASLN) but has lowered the price target from $15 to $10.

March 13, 2024 | 11:41 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Piper Sandler maintains an Overweight rating on ASLAN Pharma but lowers the price target from $15 to $10.
The reduction in price target by Piper Sandler, despite maintaining an Overweight rating, could lead to a negative short-term sentiment among investors. This adjustment suggests that while the outlook remains positive, there are factors that may limit the stock's upside potential in the near term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100